SCHEMBL6760263

SCHEMBL6760263

COC(=O)c1cccc(Oc2nn(Cc3ccccc3)c3ccccc23)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.49
CNR2 P34972 2/20 0.49
ACHE P22303 1/20 0.49
F2RL3 Q96RI0 1/20 0.47
KDM4E B2RXH2 2/20 0.46
CYP1A2 P05177 2/20 0.46
GUCY1B2 O75343 1/20 0.46
CHRM2 P08172 1/20 0.46
HTR1A P08908 1/20 0.46
ADRA2A P08913 1/20 0.46
CYP2D6 P10635 1/20 0.46
CHRM1 P11229 1/20 0.46
DRD1 P21728 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A4 P31645 1/20 0.46
GUCY1A2 P33402 1/20 0.46
ADRA1A P35348 1/20 0.46
OPRM1 P35372 1/20 0.46
DRD3 P35462 1/20 0.46
SLC6A3 Q01959 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6764345 0.79 CNR1 (0.54) CNR1CNR2ACHEF2RL3KDM4E
SCHEMBL6760260 0.77 CNR1 (0.50) CNR1CNR2ACHEF2RL3KDM4E
SCHEMBL1897336 0.75 PTGER4 (0.59) CNR1CNR2ACHEF2RL3CYP1A2
SCHEMBL6760246 0.74 CNR2 (0.64) CNR1CNR2ACHEF2RL3KDM4E
SCHEMBL6763555 0.74 CNR1 (0.56) CNR1CNR2ACHEF2RL3KDM4E
SCHEMBL28910049 0.74 CNR1 (0.64) CNR1CNR2ACHEF2RL3KDM4E
SCHEMBL2760339 0.73 CNR2 (0.70) CNR1CNR2ACHEF2RL3KDM4E
SCHEMBL10829748 0.73 CNR1 (0.62) CNR1CNR2ACHEF2RL3KDM4E
SCHEMBL28757989 0.71 CNR1 (0.63) CNR1CNR2ACHEF2RL3KDM4E
SCHEMBL12608904 0.71 CNR2 (0.67) CNR1CNR2ACHEF2RL3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase ABBOTT LABORATORIES 2004-03-11 US disclosed
WO-2003076408-A2 INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE ABBOTT LABORATORIES (US) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase GUCY1B1, GUCY1A1, GUCY1A2 CNR1 1179/4885CNR2 1561/4885ACHE 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.